唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松的临床疗效研究

目的:观察唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松症的临床疗效。方法:将120例糖尿病性骨质疏松患者随机分为实验组和对照组,实验组60例予唑来膦酸联合钙尔奇D治疗,对照组60例予钙尔奇D治疗。连续治疗12个月后,比较两组患者的骨密度、疼痛评分及不良反应的发生情况。结果:治疗12个月后,实验组患者的股骨颈、股骨粗隆和腰椎正位的骨密度均较对照组明显升高,差异有统计学意义(P0.05);VAS疼痛评分较对照组显著降低(P0.05)。治疗过程中,两组均无严重的不良反应发生。结论:唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松临床效果优于钙尔奇D单药治疗。

Efficacy of Zoledronic Acid plus Caltrate Don in the Treatment of Diabetic Osteoporosis

Objective:To investigate the efficacy of Zoledronic acid plus Caltrate D in the treatment of diabetic osteoporosis.Methods:120 patients diagnosed as diabetic osteoporosis were randomly divided into the experimental group and control group, 60 cases in each group. The control group was treated with Caltrate D and the experimental group was treated with CaltrateD plus Zoledronic acid for 12 months. Then the BMD points of VAS and untoward effect were compared between two groups.Results:After 12 months'' treatment, the bone mineral density of femoral neck, trochanter, and lumbar spine in the experimental group were significantly higher than those of the control group (P<0.05), and the scores of VOA was significantly lower than that of the control group (P<0.05). There were no serious adverse reactions during the treatment.Conclusion:Zoledronic acid plus Caltrate D was more effective than Caltrate D alone in the treatment of diabetic osteoporosis.